Ligand Pharmaceuticals (LGND) Debt Ratio (2011 - 2026)

Ligand Pharmaceuticals (LGND) posted Debt Ratio of 0.29 for Q1 2026, up 2.02% sequentially from 0.29 in Q4 2025.

Ligand Pharmaceuticals (LGND) Debt Ratio (2011 - 2026) Analysis & Trends

Ligand Pharmaceuticals has reported Debt Ratio for 13 years, with the latest figure at 0.29 in Q1 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.29 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.29 (changed N/A YoY) and the FY2025 annual result came in at 0.29, changed N/A from the prior year.
Debt Ratio improved to 0.29 in Q1 2026 per LGND's latest filing, from 0.29 in the prior quarter.
Over five years, Debt Ratio peaked at 0.3 in Q3 2025 and troughed at 0.07 in Q3 2022.
A 4-year average of 0.18 and a median of 0.11 in 2022 frame the typical range for Debt Ratio.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Ligand Pharmaceuticals	5.87 Bn	4.51 Bn	60.48 Mn	0.52

Download Data